Home › Calculator › PRTA Dividend Calculator 2026
PRTA Dividend DRIP Calculator 2026
20.64% YieldHealthcareProthena Corporation plc · NASDAQ
Price: $9.69 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When PRTA pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your PRTA snowball 📈
$10,000 in PRTA → $12.50M in 10 years · $209.93/month
About Prothena Corporation plc (PRTA) — Dividend Analysis 2026
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Compare PRTA with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full PRTA DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open PRTA position with:
🌍 PRTA Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold PRTA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 20.64% | 17.84% | $2,064 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 17.54% | 14.74% | $1,754 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 16.51% | 13.71% | $1,651 / yr |
| 🇬🇧 UK ISA | 0% | 20.64% | 17.84% | $2,064 / yr |
| 🇬🇧 UK Taxable | 8.75% | 18.83% | 16.03% | $1,883 / yr |
| 🇨🇦 TFSA | 0% | 20.64% | 17.84% | $2,064 / yr |
| 🇨🇦 CA Taxable | 25% | 15.48% | 12.68% | $1,548 / yr |
| 🇦🇺 Super (pension) | 15% | 17.54% | 14.74% | $1,754 / yr |
| 🇦🇺 AU Taxable | 30% | 14.45% | 11.65% | $1,445 / yr |
| 🇩🇪 DE Taxable | 26.375% | 15.20% | 12.40% | $1,520 / yr |
| 🇫🇷 FR Taxable | 30% | 14.45% | 11.65% | $1,445 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 PRTA Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 PRTA Dividend Payment Schedule
PRTA pays quarterly — 4 times per year. Next ex-div: TBD.
📊 PRTA vs Healthcare Benchmarks
How PRTA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PRTA sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ PRTA Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2026-06-16 | 20,000 | $7.90 | $158.0K | ||
| G-Gift | 2026-06-15 | 325,000 | — | — | ||
| Buy | 2026-06-11 | 125,000 | $8.17 | $1.02M | ||
| Other | 2026-06-08 | 17,500 | $10.99 | $192.3K | ||
| Other | 2026-06-08 | 10,000 | $22.60 | $226.0K | ||
| Other | 2026-06-08 | 8,250 | $32.45 | $267.7K | ||
| Other | 2026-06-08 | 8,800 | $52.97 | $466.1K | ||
| Other | 2026-06-08 | 12,000 | $30.30 | $363.6K | ||
| Other | 2026-06-08 | 8,612 | $14.95 | $128.7K | ||
| Other | 2026-06-08 | 37,500 | $9.36 | $351.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Insiders are net buyers — historically a positive signal for dividend sustainability. Last purchase: 2026-06-16
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PRTA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Prothena Corporation plc (PRTA) is currently trading at $9.69, 86% below its 52-week high. The current dividend yield is 20.64% based on an annual payout of $2.00 per share.
PRTA (Prothena Corporation plc) — 20.64% Dividend Yield Analysis
Prothena Corporation plc (PRTA) is a healthcare stock currently trading at $9.69 with a dividend yield of 20.64%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (20.64%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest PRTA News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.